Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Short term Debt (2020 - 2025)

Bioventus (BVS) has disclosed Short term Debt for 6 consecutive years, with $11.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short term Debt fell 41.49% year-over-year to $11.2 million, compared with a TTM value of $11.2 million through Sep 2025, down 41.49%, and an annual FY2024 reading of $27.3 million, changed N/A over the prior year.
  • Short term Debt was $11.2 million for Q3 2025 at Bioventus, up from $10.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $41.3 million in Q2 2023 and bottomed at $10.6 million in Q1 2025.
  • Average Short term Debt over 5 years is $23.6 million, with a median of $20.3 million recorded in 2022.
  • The sharpest move saw Short term Debt skyrocketed 240.69% in 2024, then crashed 70.48% in 2025.
  • Year by year, Short term Debt stood at $18.0 million in 2021, then soared by 83.26% to $33.1 million in 2022, then plummeted by 40.76% to $19.6 million in 2023, then surged by 39.6% to $27.3 million in 2024, then plummeted by 58.85% to $11.2 million in 2025.
  • Business Quant data shows Short term Debt for BVS at $11.2 million in Q3 2025, $10.6 million in Q1 2025, and $27.3 million in Q4 2024.